Clinical Trial Update: A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas [Phase 1]

View source ↗

Summary

A Phase I multicenter peptide vaccine trial named MultIceNTER for newly diagnosed H3 K27M-mutant glioma is active but not recruiting, sponsored by the German Ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• H3 K27m-mutant Glioma

Drugs mentioned

• MultIceNTER peptide vaccine (peptide vaccine)

Snippet

Sponsor: German Cancer Research Center | Conditions: Newly Diagnosed H3-mutated Glioma | Phase 1 | Status: ACTIVE_NOT_RECRUITING